Landmark Alzheimer’s Drug Approval Confounds Research Community

Share This Story, Choose Your Platform!

The US Food and Drug Administration (FDA) approval yesterday of the first new drug for Alzheimer’s disease in 18 years was welcomed by some people looking for hope against an intractable condition. But, for many researchers, it came as a surprise — and a disappointment. Read more…